Page 26 - Read Online

Page 20 of 20 Manrique et al. Microbiome Res Rep 2024;3:23 https://dx.doi.org/10.20517/mrr.2023.80

151. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One 2016;11:e0161174.
DOI PubMed PMC
152. Gosálbez L. Fecal microbiota transplantation (FMT): global industry and regulatory overview. Available from: https://www.
microbiometimes.com/fecal-microbiota-transplantation-fmt-global-industry-and-regulatory-overview/. [Last accessed on 15 Mar
2024].
153. Faecal microbiota transplantation. EU-IN Horizon Scanning Report. 2022. Available from: https://www.ema.europa.eu/en/
documents/report/faecal-microbiota-transplantation-eu-horizon-scanning-report_en.pdf. [Last accessed on 15 Mar 2024].
154. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal
products for human use, and repealing Directive 2001/20/EC Relevant text for EEA purposes. Available from: http://data.europa.eu/
eli/reg/2014/536/oj/spa. [Last accessed on 15 Mar 2024].
155. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). Available from: https://database.ich.org/sites/
default/files/E6_R2_Addendum.pdf. [Last accessed on 15 Mar 2024]
156. Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials.
Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-quality-documentation-
concerning-biological-investigational-medicinal-products-clinical-trials-revision-2_en.pdf. [Last accessed on 15 Mar 2024].
157. FDA. FDA approves first orally administered fecal microbiota product for the prevention of recurrence of Clostridioides difficile
infection. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-
microbiota-product-prevention-recurrence-clostridioides. [Last accessed on 15 Mar 2024].
158. BiomeBank. BiomeBank announces world first regulatory approval for donor derived microbiome drug. 2022. Available from: https:/
/www.biomebank.com/news/biomebank-announces-world-first-regulatory-approval-for-donor-derived-microbiome-drug/. [Last
accessed on 15 Mar 2024].
159. FDA. VOWST. Available from: https://www.fda.gov/vaccines-blood-biologics/vowst. [Last accessed on 15 Mar 2024]
160. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007;449:804-
10. DOI PubMed PMC
161. Oliveira FS, Brestelli J, Cade S, et al. MicrobiomeDB: a systems biology platform for integrating, mining and analyzing microbiome
experiments. Nucleic Acids Res 2018;46:D684-91. DOI PubMed PMC
162. Wu S, Sun C, Li Y, et al. GMrepo: a database of curated and consistently annotated human gut metagenomes. Nucleic Acids Res
2020;48:D545-53. DOI PubMed PMC
163. Katz K, Shutov O, Lapoint R, Kimelman M, Brister JR, O’Sullivan C. The sequence read archive: a decade more of explosive
growth. Nucleic Acids Res 2022;50:D387-90. DOI PubMed PMC
164. MIT Professional Education. Artificial intelligence vs machine learning: what’s the difference? Available from: https://
professionalprograms.mit.edu/blog/technology/machine-learning-vs-artificial-intelligence/. [Last accessed on 15 Mar 2024].
165. Russell SJ, Norvig P. Artificial intelligence : a modern approach. Third edition. Available from: https://people.engr.tamu.edu/guni/
csce421/files/AI_Russell_Norvig.pdf. [Last accessed 15 Mar 2024].
166. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature 2015;521:436-44. DOI PubMed
167. Ghannam RB, Techtmann SM. Machine learning applications in microbial ecology, human microbiome studies, and environmental
monitoring. Comput Struct Biotechnol J 2021;19:1092-107. DOI PubMed PMC
168. Acharjee A, Singh U, Choudhury SP, Gkoutos GV. The diagnostic potential and barriers of microbiome based therapeutics.
Diagnosis 2022;9:411-20. DOI PubMed
169. Ratiner K, Abdeen SK, Goldenberg K, Elinav E. Utilization of host and microbiome features in determination of biological aging.
Microorganisms 2022;10:668. DOI PubMed PMC
170. Su Q, Liu Q, Lau RI, et al. Faecal microbiome-based machine learning for multi-class disease diagnosis. Nat Commun 2022;13:6818.
DOI PubMed PMC
171. Wani AK, Roy P, Kumar V, Mir TUG. Metagenomics and artificial intelligence in the context of human health. Infect Genet Evol
2022;100:105267. DOI
172. Marcos-Zambrano LJ, Karaduzovic-Hadziabdic K, Loncar Turukalo T, et al. Applications of machine learning in human microbiome
studies: a review on feature selection, biomarker identification, disease prediction and treatment. Front Microbiol 2021;12:634511.
DOI PubMed PMC
173. Radjabzadeh D, Bosch JA, Uitterlinden AG, et al. Gut microbiome-wide association study of depressive symptoms. Nat Commun
2022;13:7128. DOI PubMed PMC
174. Sudhakar P, Machiels K, Verstockt B, Korcsmaros T, Vermeire S. Computational biology and machine learning approaches to
understand mechanistic microbiome-host interactions. Front Microbiol 2021;12:618856. DOI PubMed PMC
175. Belcour A, Frioux C, Aite M, Bretaudeau A, Hildebrand F, Siegel A. Metage2Metabo, microbiota-scale metabolic complementarity
for the identification of key species. Elife 2020;9:e61968. DOI PubMed PMC